CRC Press Pharmaceutical Inhalation Aerosol Technology, Third Edition (Drugs and the Pharmaceutical Sciences)

This fully revised and updated third edition of Pharmaceutical Inhalation Aerosol Technology encompasses the scientific and technical foundation for the rationale, design, componentry, assembly and quality performance metrics of therapeutic inhalers in their delivery of pharmaceutical aerosols to treat symptoms or the underlying causes of disease. It focuses on the importance of pharmaceutical engineering as a foundational element of all inhaler products and their application to pulmonary drug delivery. The expanded scope considers previously unaddressed aspects of pharmaceutical inhalation aerosol technology and the patient interface by including aerosol delivery, lung deposition and clearance that are used as measures of effective dose delivery. Key Features: Provides a thoroughly revised and expanded reference with authoritative discussions on the physiologic,pharmacologic, metabolic, molecular, cellular and physicochemical factors, influencing the efficacy and utilization of pharmaceutical aerosols Emphasizes the importance of pharmaceutical engineering as a foundational element of all inhaler products and their application to pulmonary drug delivery Addresses the physics, chemistry and engineering principles while establishing disease relevance Expands the ‘technology’ focus of the original volumes to address the title more directly Offers an impressive breadth of coverage as well as an international flavour from outstanding editors and contributors Review This is a comprehensive reference on the scientific and regulatory aspects of inhaled aerosol drug delivery systems. The field of pharmaceutical aerosols has been growing. This edition is expected to be well received by the audience. There are only a couple of books on this subject, but they are not comprehensive. Therefore, this is a must-have reference for scientists working in this field. - Rahmat M. Talukder, The University of Texas at Tyler About the Author Dr. Hickey is a Distinguished Fellow at the Research Triangle Institute, Emeritus Professor of Molecular Pharmaceutics of the Eshelman School of Pharmacy (2010-present, Professor 1993-2010) and Adjunct Professor Biomedical Engineering in the School of Medicine, at the University of North Carolina at Chapel Hill. He obtained Ph.D. (1984) and D.Sc. (2003) degrees in pharmaceutical sciences from Aston University, Birmingham, UK. Following postdoctoral positions, at the University of Kentucky (1984-1988) Dr. Hickey joined the faculty at the University of Illinois at Chicago (1988-1993). In 1990 he received the AAPS Young Investigator Award in Pharmaceutics and Pharmaceutical Technology. He is a Fellow of the Royal Society of Biology (2000), the American Association of Pharmaceutical Scientists (2003) and the American Association for the Advancement of Science (2005). He is the founder (1997, and formerly President and CEO, 1997-2013) of Cirrus Pharmaceuticals, Inc., which was acquired by Kemwell Pharma in 2013; founder (2001, and formerly CSO, 2002-2007) of Oriel Therapeutics, Inc, which was acquired by Sandoz in 2010 and founder and CEO of Astartein, Inc. (2013-present); member of the Pharmaceutical Dosage Forms Expert Committee of the United States Pharmacopeia (USP, 2010–2015, Chair of the sub-committee on Aerosols) and formerly Chair of the Aerosols Expert Committee of the USP (2005-2010). Dr. Hickey conducts a multidisciplinary research program in the field of pulmonary drug and vaccine delivery for treatment and prevention of a variety of diseases. Dr. da Rocha is an Associate Professor of Pharmaceutics in the School of Pharmacy, holds a joint appointment in Chemical and Life Science Engineering, and is also a member of the Massey Cancer Center at Virginia Commonwealth University (VCU). He obtained his Ph.D. in 2000 from the University of Texas at Austin in Chemical Engineering. After a postdoctoral position in Chemistry and Biochemistry also at the Univ